Total Payments
$585,803
2024 Payments
$66,627
Companies
27
Transactions
416
Medicare Patients
567
Medicare Billing
$34,395
Payment Breakdown by Category
Consulting$403,123 (68.8%)
Travel$156,143 (26.7%)
Food & Beverage$12,033 (2.1%)
Research$8,702 (1.5%)
Other$5,803 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $403,123 | 85 | 68.8% |
| Travel and Lodging | $156,143 | 132 | 26.7% |
| Food and Beverage | $12,033 | 187 | 2.1% |
| Unspecified | $8,702 | 10 | 1.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,803 | 2 | 1.0% |
Payments by Type
General
$577,101
406 transactions
Research
$8,702
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharma AG | $183,812 | 98 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $73,604 | 25 | $0 (2024) |
| GlaxoSmithKline, LLC. | $54,837 | 46 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $36,862 | 51 | $0 (2023) |
| AstraZeneca UK Limited | $34,003 | 46 | $0 (2024) |
| AstraZeneca AB | $31,205 | 27 | $0 (2022) |
| ROCHE DIAGNOSTICS INTERNATIONAL LTD | $29,664 | 19 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $24,850 | 31 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $22,400 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $19,511 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $66,627 | 39 | Alexion Pharmaceuticals, Inc. ($22,400) |
| 2023 | $41,995 | 24 | Bayer Healthcare Pharmaceuticals Inc. ($17,287) |
| 2022 | $58,235 | 29 | Bayer HealthCare Pharmaceuticals Inc. ($26,858) |
| 2021 | $60,832 | 12 | GlaxoSmithKline, LLC. ($20,090) |
| 2020 | $96,479 | 31 | Novartis Pharma AG ($35,076) |
| 2019 | $83,514 | 103 | Novartis Pharma AG ($55,753) |
| 2018 | $99,310 | 104 | Novartis Pharma AG ($44,892) |
| 2017 | $78,811 | 74 | Novartis Pharma AG ($28,853) |
All Payment Transactions
416 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| 12/04/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,955.00 | General |
| 11/16/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $32.72 | General |
| 11/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Cardio-renal | ||||||
| 11/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $74.28 | General |
| Category: Cardio-renal | ||||||
| 11/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $70.00 | General |
| Category: Cardio-renal | ||||||
| 11/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $34.37 | General |
| Category: Cardio-renal | ||||||
| 11/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $34.37 | General |
| Category: Cardio-renal | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $159.77 | General |
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $59.74 | General |
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $59.10 | General |
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $21.49 | General |
| 10/07/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 10/04/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| Category: Genetic Disease | ||||||
| 09/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Cardio-renal | ||||||
| 09/03/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 08/07/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: Cardiovascular Diseases | ||||||
| 06/24/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 05/31/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $7,414.00 | General |
| 05/20/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,950.00 | General |
| 05/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $42.94 | General |
| 05/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $14.31 | General |
| 05/10/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $4,935.00 | General |
| 05/10/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | Cash or cash equivalent | $296.08 | General |
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $55.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A 24-week Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase 2 Dose Ranging Trial of BMS -986224 Added to the Standard of Care in Patients with Chronic Stable Heart failure with reduced Ejection Fraction | E.R. Squibb & Sons, L.L.C. | $5,000 | 1 |
| Consultation agreement with Scott Solomon managed by CPC | Bayer Healthcare Pharmaceuticals Inc. | $1,800 | 2 |
| LCH-PO-98754 RACIAL AND ETHNIC DIFFERENCES IN NT-PROBNP CONCENTRATIONS AND REVERSE CARDIAC REMODELING IN PATIENTS WITH SYSTOLIC HEART FAILURE | NOVARTIS PHARMACEUTICALS CORPORATION | $614.00 | 1 |
| LCH-PO-98755 SEX-BASED DIFFERENCES IN BIOMARKERS QUALITY OF LIFE & REVERSE CARDIAC REMODELING IN PATIENTS WITH HFREF TREATED WITH SACUBITRIL/VALSARTAN | NOVARTIS PHARMACEUTICALS CORPORATION | $614.00 | 1 |
| LCH-PO-98830 ATRIAL NATRIURETIC PEPTIDE MEDIATES REVERSE CARDIAC REMODELING DURING TREATMENT WITH SACUBITRIL/VALSARTAN IN PATIENTS WITH HFREF | NOVARTIS PHARMACEUTICALS CORPORATION | $519.00 | 1 |
| GALACTIC - HF | Amgen Inc. | $82.50 | 1 |
| Ph 2 PO Study | Amgen Inc. | $66.94 | 2 |
| GALACTIC-HF | Amgen Inc. | $5.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 37 | 47 | $18,991 | $3,523 |
| 2022 | 3 | 93 | 98 | $40,859 | $7,757 |
| 2021 | 5 | 231 | 239 | $66,611 | $13,031 |
| 2020 | 6 | 206 | 213 | $48,152 | $10,084 |
Total Patients
567
Total Services
597
Medicare Billing
$34,395
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 37 | 47 | $18,991 | $3,523 | 18.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 35 | $13,965 | $2,634 | 18.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 37 | 37 | $11,016 | $2,109 | 19.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 14 | 14 | $9,170 | $1,733 | 18.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $6,708 | $1,281 | 19.1% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2021 | 128 | 129 | $38,700 | $7,267 | 18.8% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 33 | 33 | $14,196 | $2,816 | 19.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 26 | 33 | $11,292 | $2,437 | 21.6% |
| 93308 | Follow-up or limited ultrasound examination of heart | Facility | 2021 | 12 | 12 | $1,245 | $264.36 | 21.2% |
| 93356 | Heart muscle strain imaging | Facility | 2021 | 21 | 21 | $1,024 | $215.96 | 21.1% |
| 93325 | Doppler ultrasound study of color-directed heart blood flow, rate, and valve function | Facility | 2021 | 11 | 11 | $154.00 | $29.92 | 19.4% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2020 | 99 | 100 | $29,502 | $6,222 | 21.1% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2020 | 17 | 17 | $7,158 | $1,461 | 20.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 22 | 27 | $5,553 | $1,134 | 20.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 14 | 15 | $3,080 | $638.94 | 20.7% |
| 93308 | Follow-up or limited ultrasound examination of heart | Facility | 2020 | 21 | 21 | $2,173 | $481.83 | 22.2% |
| 93321 | Follow-up or limited heart doppler ultrasound study of heart blood flow, valves, and chambers | Facility | 2020 | 14 | 14 | $420.00 | $92.14 | 21.9% |
| 93325 | Doppler ultrasound study of color-directed heart blood flow, rate, and valve function | Facility | 2020 | 19 | 19 | $266.00 | $53.59 | 20.1% |
About Dr. Scott Solomon, MD
Dr. Scott Solomon, MD is a Cardiovascular Disease healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528025996.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Solomon, MD has received a total of $585,803 in payments from pharmaceutical and medical device companies, with $66,627 received in 2024. These payments were reported across 416 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($403,123).
As a Medicare-enrolled provider, Solomon has provided services to 567 Medicare beneficiaries, totaling 597 services with total Medicare billing of $34,395. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Boston, MA
- Active Since 04/28/2006
- Last Updated 03/11/2019
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1528025996
Products in Payments
- LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) $58,319
- FARXIGA (Drug) $48,775
- ENTRESTO (Drug) $47,244
- LCZ696D (Drug) $33,156
- LCZ696B (Drug) $32,815
- LCZ696D_ENTRESTO_CARDIOVASCULAR (Drug) $27,164
- CD Middleware Solutions (Device) $13,885
- FLUZONE HIGH-DOSE (Biological) $11,260
- INJECTAFER (Drug) $10,836
- CLINICAL TRIAL PRODUCT (Device) $10,000
- CD cobas Reagents (Device) $8,678
- LCZ696 (Drug) $7,517
- Kerendia (Drug) $5,560
- INVOKANA (Drug) $5,286
- ENTRESTO_ENTRESTO_CARDIOVASCULAR (Drug) $5,148
- DIOVAN (Drug) $3,358
- AMVUTTRA (Drug) $2,820
- RDI Research (Device) $2,429
- JARDIANCE (Drug) $1,300
- Non-Covered $565.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Boston
Dr. Elizabeth Nabel, M.d, M.D
Cardiovascular Disease — Payments: $3.0M
Cardiovascular Disease $3.0M
Kenneth Rosenfield, M.d, M.D
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Eric Secemsky, Md, Msc, MD, MSC
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Benjamin Scirica, M.d, M.D
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Jorge Plutzky, Md, MD
Cardiovascular Disease — Payments: $973,823
Cardiovascular Disease $973,823
Christopher Cannon, Md, MD
Cardiovascular Disease — Payments: $869,405
Cardiovascular Disease $869,405